Clinical Trial Results:
A multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the renal hemodynamic effects of RLX030 at a dose of 30 μg/kg/day or placebo infused for 24 hours in subjects with chronic heart failure (CHF).
Summary
|
|
EudraCT number |
2011-001588-37 |
Trial protocol |
DE NL PL |
Global completion date |
20 Dec 2012
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
07 Oct 2016
|
First version publication date |
07 Oct 2016
|
Other versions |
|
Summary report(s) |
CRLX030A2202.CTR.01Sept2016 |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.